Why Does My Insurance Make Me Try Avastin First?
Why Your Plan Asks for Avastin First: The Short Answer
Your plan wants you to start with the cheaper drug. This rule is called step therapy. Some people call it 'fail first.' It is a cost rule written by your plan. It is not a judgment about your eye.
Medicare Advantage plans have been allowed to use step therapy for office-given Part B drugs, including eye injections, since 2019. The rule lets a plan ask you to try its preferred drug before it pays for a different one.1
The first drug is a real treatment, not a placeholder. Your doctor can also ask for an exception if Avastin is a poor fit for your eye.
Mostly it is a cheaper one. Avastin (generic name bevacizumab) is the same class of drug as the pricier options. All of them block a growth signal called VEGF that makes leaky vessels grow under the retina.
In the CATT trial of 1,185 people with wet macular degeneration, bevacizumab and ranibizumab (Lucentis) gave equivalent vision results on the same schedule.2 A review of national treatment guidelines reached the same practical conclusion: no clinically significant difference in effectiveness or safety among aflibercept, bevacizumab and ranibizumab.3
One exception matters, and it involves diabetic swelling with poor starting vision. It is covered below, and it is the strongest reason to ask for a different drug up front.
A step therapy rule has limits, and knowing them saves a lot of worry. In Medicare Advantage, a plan may generally apply Part B step therapy only when you are starting a new medication, so someone already receiving a Part B drug cannot be forced to switch to the plan's preferred drug.4
The rule also does not decide how often you are treated. Your retina specialist still sets the schedule, examines the eye and orders the scans that show whether the swelling is settling.
The Drugs Your Plan Is Weighing Against Each Other
Avastin was built as a cancer drug and is given into a vein for that use. The FDA-approved uses listed on the Avastin (bevacizumab) label are cancer indications, and the label carries no approved eye indication.5 Retina specialists use a tiny fraction of a vial in the eye, and that use is off-label.
Off-label sounds alarming and usually is not. It means a licensed doctor is using an approved drug for a purpose the label does not list, which is legal and common. The American Academy of Ophthalmology tells patients that Avastin is used off-label in the eye, while Lucentis, Eylea, Eylea HD and Vabysmo are FDA-approved for use in the eye.6
These two were developed and tested for eye disease, then approved for it. The maker packages them as single eye doses, so no outside pharmacy has to divide a vial.
That is a real advantage in one narrow sense: dosing and packaging were designed for this exact job. It is not, by itself, evidence that your vision will end up better. The trials settle that question.
You may hear about drugs made to last longer between injections, such as Vabysmo (faricimab) or the higher-dose version of Eylea. You may also hear about biosimilars, which are close copies of Lucentis or Eylea made by other companies.
Plans revise their preferred list every year, and the preferred product is not always Avastin. Ask your plan which product it prefers this year.
The short version is that the evidence arrived and the price gap never closed. Anti-VEGF injection is the first-line treatment for wet age-related macular degeneration, and the choice of product is meant to rest with the treating ophthalmologist and the patient wherever possible.7
Roughly half of ophthalmologists reach for Avastin first, weighing effectiveness, cost and insurance rules together.6 Your plan did not invent that habit. It built a rule around a choice many doctors were already making.
Avastin Versus the Eye-Approved Drugs, Side by Side
The clearest test of 'Avastin first' is the Protocol AC trial. It compared starting with bevacizumab against starting with aflibercept, in eyes with diabetic macular swelling and vision of 20/50 to 20/320. Vision is scored in letters read on an eye chart, and about five letters is one line.
| Starting strategy | Average vision gain at 2 years | Estimated 2-year cost per eye |
|---|---|---|
| Bevacizumab first, switch to aflibercept if the response is not enough | About 14.0 letters, close to 3 lines | About 13,900 dollars |
| Aflibercept from the start | About 15.0 letters, close to 3 lines | About 26,500 dollars |
There was no significant difference in two-year vision between the two strategies, and about 70 of every 100 bevacizumab-first eyes were switched to aflibercept along the way.89 Read that switching figure carefully: the strategy worked because switching happened when it was needed, not because bevacizumab carried every eye alone.
One finding matters most if you have diabetic macular swelling and your vision has already dropped. In the Protocol T trial of 660 adults, eyes starting at 20/50 or worse gained about 18.9 letters with aflibercept versus about 11.8 letters with bevacizumab at one year, while eyes starting at 20/32 to 20/40 gained about the same amount on all three drugs.10
That gap is roughly a line and a half of vision in the first year, in one specific group. If your starting vision sits in that range, it is a concrete, citable reason for your doctor to request an exception.
No page can tell you which drug belongs in your eye. What follows is the pattern the trials support, to be checked against your own scans by the doctor who examines you.
- Wet macular degeneration: the trials found equivalent results on the same schedule, so starting with Avastin is reasonable.2
- Diabetic macular swelling with mild vision loss around 20/32 to 20/40: results were similar across drugs.10
- Diabetic macular swelling with vision 20/50 or worse: aflibercept had an edge at one year, worth raising before you start.10
- A previous poor response or a reaction to one agent: this is exception territory, and your record should say so.4
What Trying Avastin First Actually Involves
There is no national number. Each plan writes its own threshold into its coverage policy, so ask the injection coordinator at your retina office to read you the exact requirement.
The threshold is usually not an arbitrary hurdle. Plans tend to set it near the initial run of injections a retina specialist would give anyway before judging how an eye is responding, so the plan rule and the clinical plan often point the same way.
Your doctor is not guessing. The decision rests on a scan called OCT that measures retinal thickness, on your letter score at each visit, and on whether new bleeding shows up on examination.
Fluid that stops shrinking, thickness that creeps back up, or a letter score sliding down are the usual signals to change drugs. Ask to see your own OCT images side by side, since the trend is easier to follow than any single number.
People often fear that months on Avastin will be wasted if they end up on Eylea anyway. Protocol AC argues otherwise. The group that started on bevacizumab and switched when needed finished two years in much the same place as the group that never switched.8
Whether the injections happened on schedule matters far more than which drug came first. Gaps in treatment, not the brand on the syringe, are what let fluid come back.
Risks, Trade-Offs and What the Numbers Really Say
Every drug in this class shares the same short list of common effects: a red spot on the white of the eye, mild soreness, and blurring for a few hours. These settle on their own in most people.
The rare but serious risk is infection inside the eye, called endophthalmitis. In the CATT trial it occurred in 6 of 1,185 patients over the first year, so roughly 5 of every 1,000 people treated.2 It is uncommon and treatable when caught early, and the warning signs are listed later on this page.
A vial of Avastin holds far more than one eye needs, so a compounding pharmacy divides it into single-eye syringes. That extra step is the honest downside of the cheaper option.
Contaminated batches have been linked to documented clusters of eye infection, which is why the standards of the repackaging facility matter.11 The useful response is a question, not worry. Ask your retina office which outsourcing facility supplies their syringes. Established practices expect that question and have an answer ready.
The picture is reassuring but not perfectly clean, and you deserve both halves. In the CATT trial, serious whole-body events were reported in about 24 of every 100 bevacizumab patients and about 19 of every 100 ranibizumab patients. The authors said that gap could reflect chance, or health differences at the start, rather than the drug.2
A Cochrane review later pooled nine randomized trials with 3,665 people. It found no clear difference in deaths or serious whole-body side effects between the two drugs over two years, apart from a signal for stomach and bowel problems in a secondary analysis.12 The larger pool did not confirm the early signal. That is the usual pattern when a small imbalance turns out to be noise.
Averages describe groups, and your eye is not a group. In Protocol AC, the average treated eye gained close to three lines of vision over two years.8 Some eyes gained more, and others lost ground despite good treatment.
The starting drug matters far less to your outcome than starting soon and keeping every appointment. That is the part you and your doctor control.
How to Ask for an Exception If Avastin Is Not Right for You
You can, and so can your doctor on your behalf. Medicare Advantage plans that use Part B step therapy must offer a way to request an exception, and you can appeal if the request is denied.1
Commercial plans run similar processes under other names, such as prior authorization override or medical necessity review. Call the member services number on your card, ask for the form name, then hand it to your retina office.
A strong request is specific. Vague statements of preference are the most common reason one comes back denied.
- Your diagnosis and your current vision in the affected eye, as a letter score or as a 20/40-style measurement.
- A clinical reason the preferred drug is a poor fit, such as diabetic swelling with vision of 20/50 or worse, a documented prior non-response, or a reaction to the drug.
- The trial evidence behind the request, cited by name, such as Protocol T for the poorer-vision diabetic group.10
- What is likely to happen to the eye during the delay, stated in plain clinical terms.
Plans work on defined clocks, not open-ended timelines. That is useful to know when an office tells you they are 'waiting to hear back.' Standard requests are generally decided within days, and an expedited request moves faster when your doctor certifies that waiting could seriously harm your health.4
Write down the date you filed, the reference number and who you spoke with. If the clock runs out without an answer, that record is what escalates the request.
A denial is the first stop, not the last. You have appeal rights, and the written notice of denial must explain how to use them.1
Three steps help. Ask for a peer-to-peer review, where your retina specialist speaks with the plan's physician reviewer. Ask for the coverage criteria in writing. Ask about the drug maker's patient assistance program. Meanwhile, keep getting the covered drug, because being treated with the second choice beats being untreated.
When to Call Your Retina Team
Most injection days pass without incident, and the symptoms below are uncommon. They are worth memorizing because acting the same day is what keeps a treatable problem from becoming a permanent one.
- Severe eye pain that builds over hours instead of easing.
- Sudden vision loss, or vision that gets worse rather than better a day or two after an injection.
- Increasing redness with thick discharge, or a lid you cannot open.
- A shower of new floaters, flashing lights, or a dark curtain moving across your sight.
Call your retina office immediately if any of these appear, even at night or on a weekend, and use the emergency room if you cannot reach anyone. Infection inside the eye and retinal detachment can both be treated, and outcomes are generally better the sooner treatment starts, which is what the same-day call buys you.
An insurance delay on a pill often means a few missed doses. An insurance delay on an eye injection can mean weeks of continued leaking under the retina, and vision lost to long-standing swelling does not always come back.
If your paperwork has stalled for a week or two, call the retina office and say plainly that you are worried about a treatment gap. Many practices can bridge you with the covered drug while the appeal continues.
Keep every scheduled visit even if the drug question is unresolved. Scans taken during the wait show what the delay is doing, and that record often becomes the strongest evidence in the appeal.
Bring your own log: injection dates, which drug, and how your vision felt afterward.
Questions Patients Ask About Avastin and Insurance
Your plan is deciding what it will pay for, not what may be injected. Your doctor still chooses the treatment and can request an exception with clinical justification. In practice the two decisions are tangled, which is why the exception process exists. If a plan's rule conflicts with what your eye needs, the answer is a documented request and an appeal.
For wet macular degeneration, the head-to-head evidence says the vision results are equivalent when the drugs are given on the same schedule.2 A review of national guidelines found no clinically significant difference in effectiveness or safety among the three main drugs.3 The important variable is the injection schedule and whether you keep to it, not which of the two drugs is in the syringe.
Price here reflects development and approval history, not manufacturing cost. Eylea and Lucentis were developed, tested and approved for eye use, and they are priced as eye drugs. Avastin is priced as a cancer drug, then divided into many small eye doses, spreading that cost thin. In the Protocol AC cost analysis, two years of bevacizumab-first care cost roughly half of aflibercept.9
Generally no, in Medicare Advantage. Part B step therapy may be applied when you start a new medication, and someone already receiving a Part B drug cannot be required to switch to the plan's preferred drug.4 Commercial plans vary more, so ask specifically about continuity of care or grandfathering when you renew. If a switch letter arrives while you are stable, call your retina office before you agree to anything.
Yes on both counts. A licensed physician may use an approved drug for a purpose the label does not list, and eye use of bevacizumab has been tested in large randomized trials.2 The Academy's own patient materials describe Avastin as used off-label in the eye while Lucentis and Eylea are approved for eye use.6 Off-label describes the label, not the quality of the drug.
Retina specialists usually judge the early response after an initial run of monthly injections, using scan measurements alongside your letter score. That is also around when many plans will consider a change of drug. Give the first drug that fair trial if your doctor agrees it is reasonable, then ask for a clear decision at that point rather than drifting through months of unchanged fluid.
More Questions About Cost, Switching and Coverage
Your share depends on your plan design, not on the drug's list price alone. Under Medicare Part B, coinsurance is typically a share of the allowed amount, so a costlier drug generally means a larger bill for you unless supplemental coverage absorbs it. Ask the billing office for a written estimate for each drug being considered. Patients are often surprised that the cheaper drug lowers their own bill too.
Once your doctor documents a poor response, the switch request usually moves through the plan in days rather than weeks. Expedited handling is available when a delay would risk your health.4 In the Protocol AC trial, switching was built into the plan and happened for about 70 of every 100 bevacizumab-first eyes. Needing a switch is an expected step, not a failure.9
The two-year trial evidence does not support that fear for the groups studied. Eyes that started on bevacizumab and switched when the response was not enough ended up with vision close to eyes that had aflibercept throughout.8 The larger risk to your eventual vision is a treatment gap while paperwork is unresolved, which is why keeping appointments during an appeal matters more than the order of the drugs.
Bring these to your next injection visit and write the answers down.
- Which drug does my plan require first this year, and how many injections before we can request something else?
- Given my diagnosis and my current vision, is there a clinical reason to request an exception now rather than later?
- What measurements on my scan will tell us this drug is or is not doing enough?
- Which outsourcing facility supplies your bevacizumab syringes?
- If we request an exception, who in this office files it, and how will I know the plan has answered?
- What should I do, and whom should I call, if my vision changes suddenly between visits?
- Centers for Medicare and Medicaid Services (2018). Medicare Advantage Prior Authorization and Step Therapy for Part B Drugs (fact sheet).
- New England Journal of Medicine / CATT Research Group (free full text via PubMed Central) (2011). Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration (CATT, 1-year results).
- Canadian Agency for Drugs and Technologies in Health (CADTH), via NCBI Bookshelf (2023). Anti-Vascular Endothelial Growth Factor Drugs for Age-Related Macular Degeneration: rapid review of clinical practice guidelines.
- National Council on Aging (2024). Medicare Step Therapy: How Part B Drug Coverage Works.
- US Food and Drug Administration, Drugs@FDA label archive (2016). AVASTIN (bevacizumab) prescribing information, BLA 125085.
- American Academy of Ophthalmology, EyeSmart patient education (2024). Comparison of Anti-VEGF Treatments for Wet AMD (Avastin, Eylea, Lucentis).
- American Academy of Ophthalmology (2024). Age-Related Macular Degeneration Preferred Practice Pattern.
- New England Journal of Medicine 2022;387(8):692-703 (PubMed record) (2022). Aflibercept Monotherapy or Bevacizumab First for Diabetic Macular Edema (DRCR Retina Network Protocol AC).
- Journal of VitreoRetinal Diseases / ASRS Health Economics Committee (free full text via PubMed Central) (2024). Bevacizumab First in DRCR Protocol AC vs Real-World Physician Treatment Choice for Diabetic Macular Edema: Two-Year Cost Analysis.
- New England Journal of Medicine / DRCR Retina Network (free full text via PubMed Central) (2015). Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema (DRCR Retina Network Protocol T).
- Emerging Infectious Diseases, Centers for Disease Control and Prevention (2015). Endophthalmitis Outbreak Associated with Repackaged Bevacizumab.
- Cochrane Database of Systematic Reviews (Moja L, et al.; free full text via PubMed Central) (2014). Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration (Cochrane Review CD011230).